Clinical non‐response at · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes clinical non‐response at compared with other psychological therapies (very low certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes treatment acceptability at post‐treatment Dropout rates compared with other psychological therapies (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes treatment acceptability at compared with other psychological therapies (very low certainty).
1 finding from 1 review
Clinical non‐remission at post‐treatment · patients with depression
It is very uncertain whether mindfulness‐based 'third wave' cognitive and behavioural therapies changes non‐remission at post‐treatment compared with other psychological therapies (very low certainty).
1 finding from 1 review
Depression levels at post‐treatment (HAM‐D) · patients with depression
1 finding from 1 review
Depression levels at · patients with depression
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Quality of life at 3 months · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms
It is very uncertain whether escitalopram changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of PTSD symptoms ‐ Clinician‐rated · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
1 finding from 1 review
PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms
It is very uncertain whether hydrocortisone changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found